Results 21 to 30 of about 149,361 (217)

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Journal of Hematology & Oncology, 2016
Background Persons with acute leukemia relapsing after allotransplant and who respond to anti-leukemia interventions are at high risk of a second relapse.
Chen-Hua Yan, Yu Wang, Jing-Zhi Wang, Yu-Hong Chen, Yao Chen, Feng-rong Wang, Yu-Qian Sun, Xiao-Dong Mo, Wei Han, Huan Chen, Xiao-hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang   +13 more
doaj   +1 more source

FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study

Turkish Journal of Hematology, 2018
Objective: This study aimed to evaluate DNMT3A exon 23 mutations and their prognostic impacts in the presence of NPM1 and FLT3 mutations in acute myeloid leukemia (AML) patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT ...
Majid Teremmahi Ardestani, Ahmad Kazemi, Bahram Chahardouli, Saeed Mohammadi, Mohsen Nikbakht, Shahrbano Rostami, Mahdi Jalili, Mohammad Vaezi, Kamran Alimoghaddam, Ardeshir Ghavamzadeh   +9 more
doaj   +1 more source

Regulation of boundary cap neural crest stem cell differentiation after transplantation [PDF]

, 2009
Success of cell replacement therapies for neurological disorders will depend largely on the optimization of strategies to enhance viability and control the developmental fate of stem cells after transplantation.
Hjerling-Leffler, J, Aldskogius, Hakan, Wegner, M, Hjerling-Leffler, Jens, Kozlova, Elena N, Medvinsky, Alexander, Berens, C, Aldskogius, H, Kozlova, EN, Berens, Christian, Kanaykina, Nadezda, Sandelin, Martin, Schreiner, S, Wegner, Michael, Kanaykina, N, Sandelin, M, Liakhovitskaia, A, Medvinsky, A, Liakhovitskaia, Anna, Schreiner, Silke   +19 more
core   +1 more source

Novel_circ_003686 regulates the osteogenic differentiation of MSCs in patients with myeloma bone disease through miR-142-5p/IGF1 axis

Journal of Bone Oncology, 2023
Objectives: Circ_003686 is a novel_circRNA with abnormally low expression found in the samples of multiple myeloma bone disease (MBD) patients. The current research intended to investigate the effects of novel_circ_003686 in osteogenesis-induced ...
Ling Qiu, Lei Ma, Dan Chen, Nan Zhang, Jiao Cai, Qian Zhang, Xiao Wang, Hai Yi, Hao Yao, Fang-Yi Fan   +9 more
doaj   +1 more source

Patient reported outcomes in view of symptom experience of late effects and self-management of adult long-term survivors after allogeneic haematopoietic stem cell transplantation - a mixed methods study [PDF]

, 2014
Even years after allogeneic stem cell transplantation, recipients face a continuing risk of developing serious late effects. Previous studies have focused on the pathophysiological understanding of late effects, as well as on treatment and disease ...
Kirsch, Monika
core   +1 more source

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation

Chinese Journal of Cancer, 2016
Background Acute myeloid leukemia (AML) with t(8;21) is a heterogeneous disease. Identifying AML patients with t(8;21) who have a poor prognosis despite achieving remission is important for determining the best subsequent therapy.
Ya-Zhen Qin, Yu Wang, Hong-Hu Zhu, Robert Peter Gale, Mei-Jie Zhang, Qian Jiang, Hao Jiang, Lan-Ping Xu, Huan Chen, Xiao-Hui Zhang, Yan-Rong Liu, Yue-Yun Lai, Bin Jiang, Kai-Yan Liu, Xiao-Jun Huang   +14 more
doaj   +1 more source

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial

Frontiers in Oncology, 2023
BackgroundRefractory/relapsed acute myeloid leukemia (R/R AML) has unsatisfactory outcomes even after allogeneic hematopoietic stem cell transplantation.
Chengtao Zhang, Da Gao, Xiaohong Wang, Xiuli Sun, Yan Yan, Yan Yang, Jingjing Zhang, Jinsong Yan, Jinsong Yan, Jinsong Yan   +9 more
doaj   +1 more source

Tumor recognition by natural killer cells in acute myeloid leukemia and after hematopoietic stem cell transplantation [PDF]

, 2005
Natural killer (NK) cell-mediated cytolytic activity against tumors requires the engagement of activating NK cell receptors by the tumor-associated ligands.
Nowbakht, Pegah
core   +1 more source

Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy

Haematologica
Not available.
Wolfgang Bethge, Peter Dreger, German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy e.V. (DAG-HSZT) - German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)   +2 more
doaj   +1 more source

EDTA‐induced pseudothrombocytopenia in hematopoietic stem cell donor

Clinical Case Reports, 2023
We herein report a case of peripheral blood stem cell transplantation (PBSCT) involving a donor with EDTA‐induced pseudothrombocytopenia (PTCP). The apheresis product was inspected for 24 h and there was no platelet clumping or thrombocytopenia.
Misato Tsubokura, Minoru Kojima, Saori Nakabayashi, Noriko Takahashi, Sayaka Takeuchi, Yu Aruga, Chiaki Ikeda, Naoki Maezawa, Koji Okazaki, Sanshiro Uchida, Mizuki Watanabe, Jun Aoki, Ayumu Ito, Takashi Tanaka, Yoshihiro Inamoto, Sung‐Won Kim, Hiromichi Matsushita, Takahiro Fukuda   +17 more
doaj   +1 more source